Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
that sharply reduced progression risk and improved symptoms, a milestone the market is taking seriously. See our latest analysis for Immunome. That breakout Phase 3 readout has supercharged sentiment, with a 1 day share price return of 15.7 percent capping a 90 day share price return of 151.8 percent. The 3 year total shareholder return above 500 percent shows momentum has been building for some time. If this kind of clinical inflection has you rethinking your watchlist, it is worth exploring other innovative names in healthcare stocks that could be setting up for their own next catalyst. With shares still trading at a sizeable discount to consensus targets despite a multiyear run up, investors now face a tougher question: is Immunome still mispriced or is the market already baking in years of growth? Immunome's recent close at $22.64 comes with a rich price-to-book ratio of 7.9 times, signaling the market is paying up versus peers. The price-to-book ratio compares a compa
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Lake Street Capital.MarketBeat
- Immunome (NASDAQ:IMNM) had its price target raised by analysts at Evercore ISI from $18.00 to $40.00. They now have an "outperform" rating on the stock.MarketBeat
- Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Why Immunome Stock Surged Today [Yahoo! Finance]Yahoo! Finance
- Immunome (NASDAQ:IMNM) was given a new $40.00 price target on by analysts at Leerink Partners.MarketBeat
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 12/15/25 - Form 424B5
- 12/15/25 - Form 8-K
- 11/7/25 - Form SCHEDULE
- IMNM's page on the SEC website